Skip to main content
SpringerLink
Log in

Kombination von Zytostatika mit Strahlentherapie: Radiochemotherapie

  • Chapter
  • First Online:
Strahlentherapie

  • 9003 Accesses

Zusammenfassung

Chemo- und Strahlentherapie können simultan und sequenziell erfolgen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Amado RG, Wolf M, Peeters M et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626-34. Epub 2008 Mar 3. PubMed PMID: 18316791

    Article  PubMed  CAS  Google Scholar 

  • Ang KK, Zhang QE, Rosenthal DI et al. (2011) A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III–IV head and neck squamous cell carcinomas. J Clin Oncol; 29 (suppl; abstr. 5500)

    Google Scholar 

  • Antonadou D, Paraskevaidis M, Sarris G et al. (2002) Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20:3644–3650

    Article  PubMed  CAS  Google Scholar 

  • Aschele C, Pinto C, Cordio S et al. (2009) Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. J Clin Oncol 18S:804S; CRA4008

    Google Scholar 

  • Bengala C, Bettelli S, Bertolini F et al. (2009) Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol 20(3):469–474

    Article  PubMed  CAS  Google Scholar 

  • Berardi R, Porfiri E, Scartozzi M et al. (2003) Elderly patients with advanced non-small cell lung cancer. A phase II study with weekly cisplatin and gemcitabine. Oncology 65(3): 198–203

    Article  PubMed  CAS  Google Scholar 

  • Blackstock AW, Hess S, Chaney S et al. (1999) Oxaliplatin: in vitro evidence of its radiation sensitizing activity. Preclinical observations relevant to clinical trials. Int J Radiat Oncol Biol Phys 45:253

    Article  Google Scholar 

  • Blaszkowsky LS, Hong TS, Zhu AX, et al. (2009). A phase I/II study of bevacizumab (beva), erlotinib (erl), and 5-fluorouracil (5-FU) with concurrent external beam radiation therapy (RT) in locally advanced rectal cancer. J Clin Oncol 27:15s (suppl; abstr 4106).

    Google Scholar 

  • Bonner JA, Harari PM, Giralt J, Cohen, et al. (2010). Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer. 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28

    Article  PubMed  CAS  Google Scholar 

  • Budach W, Paulsen F, Welz S et al. (2002) Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma. Br J Cancer 86:470–476

    Article  PubMed  CAS  Google Scholar 

  • Caponigro F, Romano C, Milano A et al. (2008) A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. Anticancer Drugs 19(7):739–744

    Article  PubMed  CAS  Google Scholar 

  • Cappuzzo F, Ciuleanu T, Stelmakh L et al. (2009) SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 27:7s, (Suppl); abstr 8001

    Google Scholar 

  • Carraro S, Roca EL, Cartelli C et al. (2002) Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study. Int J Radiat Oncol Biol Phys 54:397–402

    Article  PubMed  CAS  Google Scholar 

  • Choy H, Kim DW (2003) Chemotherapy and irradiation interaction. Sem Oncol 30(Suppl 9):3–10

    Article  CAS  Google Scholar 

  • Cividalli A, Ceciarelli F, Livdi E et al. (2002) Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys 52:1092–1098

    Article  PubMed  CAS  Google Scholar 

  • Crane C, Crane CH, Eng C et al. (2010) Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 76(3):824–830

    Article  PubMed  CAS  Google Scholar 

  • Czito BG, Bendell JC, Willett CG et al. (2007) Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys 68(2):472–478

    Article  PubMed  CAS  Google Scholar 

  • Davies Cde L, Lundstrom LM, Frengen J et al. (2004) Radiation improves distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. Cancer Res 64:547–553

    Article  PubMed  Google Scholar 

  • Debucquoy A, Haustermans K, Daemen A et al. (2009). Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 27(17):2751–2757

    Article  PubMed  CAS  Google Scholar 

  • Di Petrillo T, Pricolo V, Lagares-Garcia J et al. (2009) Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation in clinical stage II-III rectal cancer J Clin Oncol 27:15s (suppl; abstr 4105)

    Google Scholar 

  • Douillard JY, Cunningham D, Roth AD et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet 355:1041–1047

    Article  PubMed  CAS  Google Scholar 

  • Dunst J, Reese T, Setter T et al. (2002) Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20:3983–3991

    Article  PubMed  CAS  Google Scholar 

  • De Lange SM, van Groeningen CJ, Mejer OWM et al. (2002) Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer 38:1212–1217

    Article  PubMed  CAS  Google Scholar 

  • Epelbaum R, Rosenblatt E, Nasrallah S et al. (2002) Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 81:138–143

    Article  PubMed  CAS  Google Scholar 

  • Erben P, Ströbel P, Horisberger K et al. (2010) KRAS & BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys [im Review]

    Google Scholar 

  • Feliu J, Calvillo J, Escribano A et al. (2002) Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy. Ann Oncol 13:730–736

    Article  PubMed  CAS  Google Scholar 

  • Flam MS, John M, Pajak T et al. (1996) Role of mitomycin C in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14:2527–2539

    PubMed  CAS  Google Scholar 

  • Freyer G, Bossard N, Romestaing P et al. (2001) Addition of oxaliplatin to continuous fluorouracil, L-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R97–03 phase I trial. J Clin Oncol 19:2433–2438

    PubMed  CAS  Google Scholar 

  • Gerard JP, Chalet O, Nemoz C et al. (2003) Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0–04 phase II trial. J Clin Oncol 21:1119–1124

    Article  PubMed  Google Scholar 

  • Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638–1644

    Google Scholar 

  • Giaccone G, Herbst RS, Manegold C et al. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1. J Clin Oncol 22:777–784

    Article  PubMed  CAS  Google Scholar 

  • Glimelius B, Jakobsen A, Graf W et al. (1998) Bolus injection (2–4 min) versus short-term (10–20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Eur J Cancer 34:674–678

    Article  PubMed  CAS  Google Scholar 

  • Glynne-Jones R, Sebag-Montefiore D, McDonald A et al. (2003) Phase I/II study of preoperative radiation and capecitabine in combination with oxaliplatin in locally advanced rectal cancer: the Socrates study. Proc Am Soc Clin Oncol 22:1174

    Google Scholar 

  • Glynne-Jones R, Meadows H, Wan S et al. (2008) EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. National Cancer Research Institute Anal Sub Group and Colorectal Clinical Oncology Group. Int J Radiat Oncol Biol Phys 72(1):119–126

    Article  PubMed  CAS  Google Scholar 

  • Glynne-Jones R, Mawdsley S, Harrison M et al. (2010) Cetuximab and chemoradiation for rectal cancer – is the water getting muddy? Acta Oncol [Epub ahead of print]

    Google Scholar 

  • Hainsworth JD, Spigel DR, Burris HA 3rd et al (2009) Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer 115(10):2138–46

    Article  PubMed  CAS  Google Scholar 

  • Hartmann JT, Oechsle K, Quietzsch D et al. (2003) Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. Br J Cancer 89:2051–2056

    Article  PubMed  CAS  Google Scholar 

  • Hassel JC, Kripp M, Al-Batran S, Hofheinz RD. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie 33(3):94-8. Epub 2010 Feb 22. PubMed PMID: 20215799

    Google Scholar 

  • Hegi ME, Diserens AC, Gorlia T et al. MGMT silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997–1003

    Google Scholar 

  • Heidelberger C, Chaudhuari NK, Danneberg P et al. (1957) Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature 179:2557–2560

    Article  Google Scholar 

  • Heidelberger C, Griesbach L, Montag BJ et al. (1958) Studies on fluorinated pyrimidines II. Effects of transplanted tumors. Cancer Res 18:305–317

    PubMed  CAS  Google Scholar 

  • Herbst RS, O’Reilly MS (2003) The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer. Sem Oncol 30(Suppl 9): 113–123

    Article  CAS  Google Scholar 

  • Herbst RS, Giaccone G, Schiller JH et al. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 22:785–794

    Article  PubMed  CAS  Google Scholar 

  • Hirose Y, Berger, Pieper RO (2001) P53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957–1963

    PubMed  CAS  Google Scholar 

  • Hoff PM, Janjan N, Saad ED et al. (2000) Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. J Clin Oncol 18:3529–3534

    PubMed  CAS  Google Scholar 

  • Hofheinz R, Hartmann J, Hartung G et al. (2003) Increasing doses of capecitabine in combination with mitomycin: a phase I study in patients with pretreated gastrointestinal cancer. Proc Am Soc Clin Oncol 22:1316

    Google Scholar 

  • Hofheinz R, von Gerstenberg-Helldorf B, Wenz F et al. (2004) Phase-I-study of irinotecan (CPT-11) and capecitabine in combination with concurrent radiotherapy for locally advanced rectal cancer. Proc Am Soc Clin Oncol 23:2203

    Google Scholar 

  • Jensen JN, Lock-Andersen J, Langer SW et al. (2003) Dexrazoxane – a promising antidote in the treatment of accidental extravasation of anthracyclines. Scand J Plast Reconstr Hand Surg 37:174–175

    Article  Google Scholar 

  • Khushalani NI, Leichman CG, Proulx G et al. (2002) Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 20:2844–2850

    Article  PubMed  CAS  Google Scholar 

  • Klautke G, Kirchner R, Hopt U et al. (2001) Continuous infusion of 5-FU and weekly irinotecan with concurrent radiotherapy as neoadjuvant treatment for locally advanced or recurrent rectal cancer. Proc Am Soc Clin Oncol 20:555

    Google Scholar 

  • Kretzschmar A, Pink D, Thuss-Patience P et al. (2003) Extravasations of oxaliplatin. J Clin Oncol 21:4068–4069

    Article  PubMed  Google Scholar 

  • Kris MG, Natale RB, Herbst RS et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer. A randomized trial. JAMA 290:2149–2158

    Article  PubMed  CAS  Google Scholar 

  • Kuten A, Anacak Y, Abdah-Bortnyak R et al. (2003) Neoadjuvant radiotherapy concurrent with weekly paclitaxel and carboplatin and followed by surgery in locally advanced non-small-cell lung cancer. Am J Clin Oncol 26:184–187

    Article  PubMed  CAS  Google Scholar 

  • Lanzetta G, Campanella C, Rozzi A et al. (2003) Temozolomide in radio-chemotherapy combination treatment for newly diagnosed glioblastoma multiforme: phase II clinical trial. Anticancer Res 23:5159–5164

    PubMed  CAS  Google Scholar 

  • Li G, Hu W, Wang J et al. (2010) Phase II Study of Concurrent Chemoradiation in Combination with Erlotinib for Locally Advanced Esophageal Carcinoma. Int J Radiat Oncol Biol Phys [Epub ahead of print] PubMed PMID: 20350790

    Google Scholar 

  • Lövey J, Koronczay K, Remenár E et al. (2003) Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer. Radiother Oncol 68:171–174

    Article  PubMed  Google Scholar 

  • Loibl S, von Minckwitz G, Schwedler K et al. (2003) Mitomycin, folinic acid, 5-FU (Mi-Fo-FU) as salvage chemotherapy for hepatic failure due to liver metastases in breast cancer. Proc Am Soc Clin Oncol 22:326

    Google Scholar 

  • Mader I, Fürst-Weger PR, Mader RM (Hrsg) (2002) Paravasation von Zytostatika. Ein Kompendium für Prävention und Therapie. Springer, Berlin Heidelberg New York Tokio

    Google Scholar 

  • Marijnen CA (2008) Preoperative chemoradiotherapy regimen with capecitabine and bevacizumab in locally advanced rectal cancer: a feasibility study of the Dutch Coloretcal Cancer Group (DCCG). J Clin Oncol 26: (suppl; abstr 15040)

    Google Scholar 

  • Marquardt F, Rödel F, Capalbo G et al. (2009) Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol 185(6):371–378

    Article  PubMed  Google Scholar 

  • Mason KA, Hunter NR, Milas M et al. (1997) Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 3:2431–2438

    PubMed  CAS  Google Scholar 

  • Maurer AM, Masters GA, Haraf DJ et al. (1998) Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16:159–164

    Google Scholar 

  • Mehta VK, Cho CC, Ford JM et al. (2003) Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 55:132–137

    Article  PubMed  Google Scholar 

  • Meyer JL, Vaeth JM (Hrsg) (1992) Radiotherapy/chemotherapy interactions in cancer treatment. Karger

    Google Scholar 

  • Molls M (1996) Prinzipien der Kombination von Radiotherapie und Chemotherapie. In: Scherer E, Sack H (Hrsg) Strahlentherapie. Radiologische Onkologie. Springer, Berlin Heidelberg New York Tokio, S 189–205

    Google Scholar 

  • Moore MJ, Goldstein D, Hamm J et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960–1966

    Article  PubMed  CAS  Google Scholar 

  • Mose S, Class R, Weber HW et al. (2002) Kombination von Radiotherapie und Gemcitabine. Bewertung klinischer Daten auf der Basis experimenteller Erkenntnisse. Strahlenther Onkol 178:59–70

    Article  PubMed  Google Scholar 

  • Mudad R, Ramsey M, Kovitz K et al. (2003) Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose finding study. Lung Cancer 39:173–177

    Article  PubMed  Google Scholar 

  • Nogue M, Salud A, Vicente P et al. (2009) Addition of bevacizumab to induction plus concomitant capecitabine-oxaliplatin (XELOX) chemoradiotherapy (CRT) in MRI poor prognosis locally advanced rectal cancer: Avacross study. J Clin Oncol 18S:193S; 4100

    Google Scholar 

  • O’Connell MJ, Martenson JA, Weiand HS et al. (1994) Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502–50

    Article  PubMed  Google Scholar 

  • Resch G, de Vries A, Öfner D et al. (2010) Preoperative treatment with capecitabine (C), bevacizumab (B), and radiotherapy (RT) for primary locally advanced rectal cancer (LARC): A two-stage phase II clinical trial. ASCO GI Cancer Symposium 2010; Abstract No. 496.

    Google Scholar 

  • Rich TA, Kirichenko AV (2001) Camptothecin schedule and timing of administration with irradiation. Oncology 15 (Suppl 5):37–41

    PubMed  CAS  Google Scholar 

  • Robert F, Ezekiel MP, Spencer SA et al. (2001) Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19:3234–3243

    PubMed  CAS  Google Scholar 

  • Rödel C, Grabenbauer GG, Papadopoulos T et al. (2003) Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 21:3098–3104

    Article  PubMed  Google Scholar 

  • Rotman M, Aziz H, Wasserman TH (1997) Chemotherapy and irradiation. In: Perez CA, Brady LW et al. (eds) Principles and Practice of Radiation Oncology. Lippincott-Raven Publishers, S 705–722

    Google Scholar 

  • Saußele S, Petzold A, Gemünden C et al. (2003) DPD deficiency in patients treated with 5-fluorouracil and capecitabine detected by melting curve analysis. Onkologie 26 (Suppl 5):793

    Google Scholar 

  • Scagliotti GV, Manegold C, Buchholz E et al. (2002) Randomized phase II study evaluating the feasibility of thoracic radiotherapy with or without weekly docetaxel (taxotere) following induction chemotherapy with cisplatin and docetaxel in unresectable stage IIIA-B non-small cell lung cancer. Proc Am Soc Clin Oncol 21:1279

    Google Scholar 

  • Shepherd, FA, Pereira, J, Ciuleanu, TE, et al. (2005) Erlotinib in previously tested non-small cell lung cancer. N Engl J Med 353,123–132

    Google Scholar 

  • Schilsky RL (1992) Biochemical pharmacology of chemotherapeutic drugs used as radiation enhancers. Sem Oncol 19 (Suppl 11):2–7

    CAS  Google Scholar 

  • Spigel DR, Greco FA, Meluch AA et al. (2010) Phase I/II Trial of Preoperative Oxaliplatin, Docetaxel, and Capecitabine With Concurrent Radiation Therapy in Localized Carcinoma of the Esophagus or Gastroesophageal Junction. J Clin Oncol 28(13):2213–2219.Epub 2010 Mar 29.

    Google Scholar 

  • Steren A, Sevin BU, Perras J et al. (1993) Taxol sensitizes human ovarian cancer cells to radiation. Gyn Oncol 48: 282–285

    Google Scholar 

  • Stupp R, Mason WP, van den Bent et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  • Tempero M, Plunkett W, Ruiz Van Haperen V et al. (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408

    Article  PubMed  CAS  Google Scholar 

  • Tepper JE, O’Connell MJ, Petroni GR et al. (1997) Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol 15:2030–2039

    PubMed  CAS  Google Scholar 

  • Tishler RB, Geard CR, Hall EJ et al. (1992) Taxol sensitizes astrocytoma cells to radiation. Cancer Res 52:3495–3497

    PubMed  CAS  Google Scholar 

  • Tony S. Mok, M.D., Yi-Long Wu, M.D. et al. (2009) Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med 361:2485–2487

    Article  Google Scholar 

  • Ulutin HC, Pak Y (2003) Preliminary results of radiotherapy with or without weekly paclitaxel in locally advanced nonsmall cell lung cancer. J Cancer Res Clin Oncol 129:52–56

    CAS  Google Scholar 

  • van Rijn J, Heimans JJ, van den Berg J et al. (2000) Survival of human glioma cells treated with various combinations of temozolomide and x-rays. Int J Radiat Oncol Biol Phys 47:779–784

    Article  PubMed  Google Scholar 

  • Velenik V, Ocvirk J, Oblak I et al. (2010) A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol 36(3):244–250

    Article  PubMed  CAS  Google Scholar 

  • Vestermark LW, Jacobsen A, Qvortrup C et al.(2008) Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC). Acta Oncol 47(3):428–433

    Article  PubMed  CAS  Google Scholar 

  • Wilkowski R, Thoma M, Heinemann V et al. (2003) Radiochemotherapie mit Gemcitabin und Cisplatin bei Pankreaskarzinom – durchführbar und effektiv. Strahlenther Onkol 179:78–86

    Article  PubMed  Google Scholar 

  • Wilkowski R, Boeck S, Ostermaier S et al. (2009) Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study. Br J Cancer 101(11):1853–1859

    Article  PubMed  CAS  Google Scholar 

  • Willett CG, Boucher Y, di Tomaso E et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10(2):145–147

    Article  PubMed  CAS  Google Scholar 

  • Willett CG, Duda DG, di Tomaso E et al. (2009) Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.J Clin Oncol 27(18):3020–3026

    Article  PubMed  CAS  Google Scholar 

  • Williams KJ, Telfer BA, Stratford IJ et al. (2001) Combination of ZD1839 (Iressa), an EGFR tyrosine kinase inhibitor, and radiotherapy increases antitumour efficacy in a human colon cancer xenograft model. Proc Am Ass Cancer Res 42:3840

    Google Scholar 

  • Workman P (1992) Infusional anthracyclines: is slower better? If so, why? Ann Oncol 3:591

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Interdisziplinäres Tumorzentrum Mannheim (ITM), TagesTherapieZentrum (TTZ), Theodor-Kutzer-Ufer 1–3, Haus 9, D-68167, Mannheim, Deutschland

    D. Gencer

Authors
  1. D. Gencer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinikum Heidelberg, Heidelberg, Germany

    Michael Wannenmacher

  2. Universitätsklinikum Mannheim, Mannheim, Germany

    Frederik Wenz

  3. Universitätsklinikum Heidelberg, Heidelberg, Germany

    Jürgen Debus

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Gencer, D. (2013). Kombination von Zytostatika mit Strahlentherapie: Radiochemotherapie. In: Wannenmacher, M., Wenz, F., Debus, J. (eds) Strahlentherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-88305-0_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-88305-0_12

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-88304-3

  • Online ISBN: 978-3-540-88305-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation